Welcome to our dedicated page for Curis news (Ticker: CRIS), a resource for investors and traders seeking the latest updates and insights on Curis stock.
Curis, Inc. (NASDAQ: CRIS) is a clinical-stage biotechnology company advancing targeted therapies for cancer treatment, with a focus on immuno-oncology and precision medicine. This page provides investors and industry stakeholders with timely updates on the company’s clinical trials, strategic collaborations, and regulatory milestones.
Access curated press releases and news articles covering Curis’s pipeline developments, including its lead candidate emavusertib, partnership updates with Aurigene and Genentech, and financial performance. The resource is designed to help users track progress across hematologic and solid tumor indications while staying informed about licensing agreements and scientific advancements.
Content spans clinical trial results, FDA designations, earnings reports, and research publications. Bookmark this page for direct access to verified updates on Curis’s innovative approaches to modulating cancer pathways and expanding treatment options.
Rhea-AI Summary
Curis, Inc. reported positive clinical data at ASH, showing 3 out of 5 patients achieved CR in R/R PCNSL. Expansion of clinical sites in the US and Europe is underway, with cash runway into 2025. The company also announced a partnership to study the combination of emavusertib and pembrolizumab in patients with metastatic melanoma. Financially, the company reported a net loss of $47.4 million for the year ended December 31, 2023, with revenues of $10.0 million and cash, cash equivalents, and investments totaling $56.3 million as of December 31, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.42%
Tags
-
News
Rhea-AI Summary
Curis, Inc. (CRIS) will release its fourth quarter 2023 financial results on February 8, 2024, and will host a conference call at 8:30 a.m. ET. The company is focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.03%
Tags
-
Rhea-AI Summary
Curis, Inc. (NASDAQ: CRIS) announced the approval of a grant of inducement stock options to a new employee, totaling 5,800 shares of Curis common stock, with a grant date of January 2, 2024. The stock option has a 10-year term and vests over four years, with 25% of the original number of shares vesting on the first anniversary of the employee's date of hire and an additional 6.25% vesting on each successive three-month period thereafter, subject to the employee's continued service with the Company. The stock option was granted as an inducement equity award outside of the Company's Fourth Amended and Restated 2010 Stock Incentive Plan and was made as an inducement material to the employee's acceptance of employment with the Company.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.87%
Tags
Rhea-AI Summary
Curis, Inc. (NASDAQ: CRIS) announces positive initial combination study data for emavusertib (CA-4948) in the TakeAim Lymphoma trial.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.61%
Tags
-
Rhea-AI Summary
Curis, Inc. (CRIS) presents positive clinical data from its TakeAim Leukemia Study at the 2023 ASH Conference, demonstrating the safety and anti-cancer activity of emavusertib in patients with FLT3 mutation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.93%
Tags
-
Rhea-AI Summary
Curis, Inc. (NASDAQ: CRIS) will present three posters at the 65th ASH Annual Meeting and Exposition, showcasing the continued progress of emavusertib (CA-4948) in clinical studies in leukemia and lymphoma. The presentations will highlight the preliminary safety and efficacy of emavusertib in acute myeloid leukemia patients with FLT3 mutation, as well as the ongoing trials evaluating the safety, PK/PD, and clinical activity of emavusertib in combination with Ibrutinib in patients with relapsed or refractory hematologic malignancies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.5%
Tags
Rhea-AI Summary
Curis, Inc. (NASDAQ: CRIS) has entered into an investigator-initiated clinical trial agreement with the University of Florida to study the combination of emavusertib and pembrolizumab in patients with metastatic melanoma. The company is responsible for supplying emavusertib, while Merck will supply pembrolizumab and cover clinical study costs. Both companies retain 100% of the commercial rights to their respective programs. The Phase 1/2 study (NCT05669352) is expected to begin enrollment in the first half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.78%
Tags
-
Rhea-AI Summary
Curis, Inc. reported its business update and financial results for Q3 2023. Patient enrollment has restarted in Phase 1/2 studies for emavusertib, with updated data expected in Q1 2024. The company plans to initiate a triplet combination study for AML in Q4 2023. Curis expects to present updated data from the TakeAim Lymphoma combination study at ASH in December. The company also highlighted a strong balance sheet with $68.5 million in cash and investments, providing a cash runway into 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.25%
Tags
-
News
Rhea-AI Summary
Curis, Inc. will release its third quarter 2023 financial results on November 2, 2023. A conference call will be held at 8:30 a.m. ET. Access details provided.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.38%
Tags
Rhea-AI Summary
Curis, Inc. approves inducement stock options for new employees
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.02%
Tags
Curis
Nasdaq:CRIS
CRIS Rankings
CRIS Stock Data
13.71M
9.56M
7.83%
37.95%
1.68%
Biotechnology
Biological Products, (no Disgnostic Substances)
United States
LEXINGTON